Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?



Biotechnology Innovation Organization

Webinar Sponsored by:



Moderator:

- Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, *Pharmaceutical Executive*; Senior Advisor, EY
- Panelists:
- Jonas Grossman, President and Managing Partner, Chardan
- Rakhi Kumar, Chief Accounting Officer, Roivant Sciences
- Ryan Maierson, Partner, Latham & Watkins LLP
- Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation
- Organization (BIO)



JUNE 10-11 & 14-18, 2021

Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership.



.

.

BIO Digital 2021 Registration Snapshot

MANAGEMENT LEVEL REGION 23% 23% **VP/Partner/** Managing 24% Director 24% 9% 9% Europe CEO/ C-Level 44% 44% North America Director/Mid-Level Manager **COMPANY SIZE** Based on employee count **300+ COMPANY PRESENTATIONS On-Demand and Ready to Partner** See List at **HOSTED BY** https://www.bio.org/events/ Bio bio-digital/company-presentations 42% 8% 11% 7% 32% Biotechnolog Innovation 1-50 51-100 500+ 101-300 301-500 Organization

Finance & Business Development Sessions at BIO Digital

Visit bio.org/bio-digital to see whole program and register

- Innovator Spotlight with Matthew Gline, Chief Executive Officer, Roivant Sciences
- Emerging Therapeutic Company Investment, By the Numbers
- Raising Capital Today, Part 1 From Start-Up to pre-IPO
- Raising Capital Today, Part 2 SPAC/IPO Paths to Public Markets
- "Mind the Gap" in Deal-Making
- Deal or No Deal? What to Know About Dealmaking Post-Pandemic
- Market Hyperactivity: Bane of Biotech Deal-makers?
- The Next Big Deal: Market Outlook for 2021 and Beyond
- A Conversation with Robert Bradway, Chief Executive Officer, Amgen
- A More Perfect Partnership: State of the Pharma and Biotech Union
- Driving Cross-Border Growth in Turbulent Times: Successes, Challenges and the Role of Ecosystems
- Financial Performance of Innovation in the Life Sciences Economy—Tracking the IPO Class through Twists and Turns



Featured BIO Digital Speakers

Visit bio.org/bio-digital to see whole program of 100+ sessions and to register



Albert Bourla, PhD, DVM Chairman and Chief Executive Officer, Pfizer Inc.



Jennifer Doudna, PhD Nobel Laureate In Chemistry; Professor of Biochemistry, Biophysics and Structural Biology, University of California, Berkeley



Anthony Fauci, MD Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health



Julie Gerberding, MD, MPH Executive Vice President and Chief Patient Officer, Merck & Co., Inc.



Laurie H. Glimcher, MD President and CEO, Dana-Farber Cancer Institute



Sanjay Gupta, MD Chief Medical Correspondent, CNN



Richard Haass, PhD President, Council on Foreign Relations



Michel Vounatsos Chief Executive Officer, Biogen



Janet Woodcock, MD Acting Commissioner, US Food & Drug Administration

Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?



Biotechnology Innovation Organization

Webinar Sponsored by:



Moderator:

- Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, *Pharmaceutical Executive*; Senior Advisor, EY
- Panelists:
- Jonas Grossman, President and Managing Partner, Chardan
- Rakhi Kumar, Chief Accounting Officer, Roivant Sciences
- Ryan Maierson, Partner, Latham & Watkins LLP
- Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation
- Organization (BIO)